nach oben

Translational Stroke Research

Erschienen in:

01.10.2015 | Opinion Paper

Critical Early Thrombolytic and Endovascular Reperfusion Therapy for Acute Ischemic Stroke Victims: a Call for Adjunct Neuroprotection

verfasst von: Paul A. Lapchak

Erschienen in: Translational Stroke Research | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Today, there is an enormous amount of excitement in the field of stroke victim care due to the recent success of MR. CLEAN, SWIFT PRIME, ESCAPE, EXTEND-IA, and REVASCAT endovascular trials. Successful intravenous (IV) recombinant tissue plasminogen activator (rt-PA) clinical trials [i.e., National Institute of Neurological Disorders and Stroke (NINDS) rt-PA trial, Third European Cooperative Acute Stroke Study (ECASSIII), and Third International Stroke study (IST-3)] also need to be emphasized. In the recent endovascular and thrombolytic trials, there is statistically significant improvement using both the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Score (mRS) scale, but neither approach promotes complete recovery in patients enrolled within any particular NIHSS or mRS score tier. Absolute improvement (mRS 0–2 at 90 days) with endovascular therapy is 13.5–31 %, whereas thrombolytics alone also significantly improve patient functional independence, but to a lesser degree (NINDS rt-PA trial 13 %). This article has 3 main goals: (1) first to emphasize the utility and cost-effectiveness of rt-PA to treat stroke; (2) second to review the recent endovascular trials with respect to efficacy, safety, and cost-effectiveness as a stroke treatment; and (3) to further consider and evaluate strategies to develop novel neuroprotective drugs. A thesis will be put forth so that future stroke trials and therapy development can optimally promote recovery so that stroke victims can return to “normal” life.

Campbell BC, Donnan GA, Davis SM. Vessel occlusion, penumbra, and reperfusion—translating theory to practice. Front Neurol. 2014;5:194. doi:10.3389/fneur.2014.00194.PubMedCentralPubMed

Davis S, Donnan GA. Time is Penumbra: imaging, selection and outcome. The Johann jacob wepfer award 2014. Cerebrovasc Dis. 2014;38(1):59–72. doi:10.1159/000365503.CrossRefPubMed

Phan TG, Wright PM, Markus R, Howells DW, Davis SM, Donnan GA. Salvaging the ischaemic penumbra: more than just reperfusion? Clin Exp Pharmacol Physiol. 2002;29(1–2):1–10.CrossRefPubMed

Lapchak PA. Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Transl Stroke Res. 2013;4(6):704–9. doi:10.1007/s12975-013-0303-0.CrossRefPubMed

Hader R, Saver C, Steltzer T. No time to lose. Nurs Manag. 2006;37(7):23–6. 8–9, 48.

Saver JL. Time is brain–quantified. Stroke. 2006;37(1):263–6.CrossRefPubMed

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322. doi:10.1161/CIR.0000000000000152.CrossRefPubMed

Hossmann KA. The two pathophysiologies of focal brain ischemia: implications for translational stroke research. J Cereb Blood Flow Metab. 2012;32(7):1310–6. doi:10.1038/jcbfm.2011.186.PubMedCentralCrossRefPubMed

Jickling GC, Sharp FR. Improving the translation of animal ischemic stroke studies to humans. Metab Brain Dis. 2014. doi:10.1007/s11011-014-9499-2.PubMed

10.

Turner RJ, Jickling GC, Sharp FR. Are Underlying Assumptions of Current Animal Models of Human Stroke Correct: from STAIRs to High Hurdles? Transl Stroke Res. 2011;2(2):138–43. doi:10.1007/s12975-011-0067-3.PubMedCentralCrossRefPubMed

11.

Lapchak PA. Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development. Transl Stroke Res. 2010;1(2):96–107. doi:10.1007/s12975-010-0018-4.PubMedCentralCrossRefPubMed

12.

Lapchak PA. A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy. Transl Stroke Res. 2015;6(2):99–103. doi:10.1007/s12975-015-0386-x.CrossRefPubMed

13.

Culp BC, Culp WC. Rabbit subselective angiography stroke model. Stroke. 2008;39(11):e165. doi:10.1161/STROKEAHA.108.526335. author reply e6.CrossRefPubMed

14.

Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483(7388):213–7. doi:10.1038/nature10841.CrossRefPubMed

15.

Cook DJ, Teves L, Tymianski M. A translational paradigm for the preclinical evaluation of the stroke neuroprotectant Tat-NR2B9c in gyrencephalic nonhuman primates. Sci Transl Med. 2012;4(154):154ra33. doi:10.1126/scitranslmed.3003824.

16.

Cook DJ, Tymianski M. Nonhuman primate models of stroke for translational neuroprotection research. Neurotherapeutics. 2012;9(2):371–9. doi:10.1007/s13311-012-0115-z.PubMedCentralCrossRefPubMed

17.

Lapchak PA. Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs. 2002;11(11):1623–32.CrossRefPubMed

18.

Desai JA, Smith EE. Prenotification and other factors involved in rapid tPA administration. Curr Atheroscler Rep. 2013;15(7):337. doi:10.1007/s11883-013-0337-5.CrossRefPubMed

19.

Olson DM, Constable M, Britz GW, Lin CB, Zimmer LO, Schwamm LH, et al. A qualitative assessment of practices associated with shorter door-to-needle time for thrombolytic therapy in acute ischemic stroke. J Neurosci Nurs. 2011;43(6):329–36. doi:10.1097/JNN.0b013e318234e7fb.CrossRefPubMed

20.

Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernandez AF, Peterson ED, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association’s Target: Stroke initiative. Stroke. 2011;42(10):2983–9. doi:10.1161/STROKEAHA.111.621342.CrossRefPubMed

21.

Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750–8. doi:10.1161/CIRCULATIONAHA.110.974675.CrossRefPubMed

22.

Saver JL, Smith EE, Fonarow GC, Reeves MJ, Zhao X, Olson DM, et al. The “golden hour” and acute brain ischemia: presenting features and lytic therapy in >30,000 patients arriving within 60 minutes of stroke onset. Stroke. 2010;41(7):1431–9. doi:10.1161/STROKEAHA.110.583815.PubMedCentralCrossRefPubMed

23.

Schrock JW, Lum M. Drill down analysis of door-to-needle time of acute ischemic stroke patients treated with intravenous tissue plasminogen activator. Am J Emerg Med. 2014;32(11):1330–3. doi:10.1016/j.ajem.2014.08.002.CrossRefPubMed

24.

Wardlaw JM, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev. 2013;5:CD000514. doi:10.1002/14651858.CD000514.pub3.PubMed

25.

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29. doi:10.1056/NEJMoa0804656.CrossRefPubMed

26.

Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, et al. Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009;8(12):1095–102. doi:10.1016/S1474-4422(09)70264-9.CrossRefPubMed

27.

NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.CrossRef

28.

Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med. 2010;5(7):406–9. doi:10.1002/jhm.689.PubMedCentralCrossRefPubMed

29.

Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals. Circ Cardiovasc Qual Outcomes. 2013;6(5):543–9. doi:10.1161/CIRCOUTCOMES.111.000303.CrossRefPubMed

30.

Ricci S, Cenciarelli S, Mazzoli T. Italian guidelines on thrombolysis indications in ischaemic stroke have been revised after IST 3 trial and Cochrane Review: PROS. Intern Emerg Med. 2013. doi:10.1007/s11739-013-0987-x.

31.

Costantino G, Podda GM, Bonzi M, Sbrojavacca R, Gruppo di Autoformazione M. Italian guidelines on thrombolysis indications in ischemic stroke have been revised after IST-3 trial and Cochrane revision: cons. Intern Emerg Med. 2013. doi:10.1007/s11739-013-0986-y.

32.

Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480–8. doi:10.1001/jama.2013.6959.CrossRefPubMed

33.

Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, et al. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials. 2011;12:252. doi:10.1186/1745-6215-12-252.PubMedCentralCrossRefPubMed

34.

Cronin CA, Smith EE. Response to letter regarding article, “Adherence to third European cooperative acute stroke study 3- to 4.5-hour exclusions and association with outcome: data from get with the guidelines-stroke”. Stroke. 2015;46(1):e16. doi:10.1161/STROKEAHA.114.007906.CrossRefPubMed

35.

Cronin CA, Sheth KN, Zhao X, Messe SR, Olson DM, Hernandez AF, et al. Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke. Stroke. 2014;45(9):2745–9. doi:10.1161/STROKEAHA.114.005443.CrossRefPubMed

36.

Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929–35. doi:10.1016/S0140-6736(14)60584-5.PubMedCentralCrossRefPubMed

37.

Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;7, CD000213. doi:10.1002/14651858.CD000213.pub3.PubMedCentralPubMed

38.

Lyden P. Why don’t more patients receive intravenous rt-PA for acute stroke? Expert Rev Neurother. 2015;15(6):571–4. doi:10.1586/14737175.2015.1041510.CrossRefPubMed

39.

Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27(9):1459–66.CrossRefPubMed

40.

Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50(4):883–90.CrossRefPubMed

41.

Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2013;61(1):46–55. doi:10.1016/j.annemergmed.2012.04.020.PubMedCentralCrossRefPubMed

42.

Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, et al. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014;45(10):3032–9. doi:10.1161/STROKEAHA.114.005852.CrossRefPubMed

43.

Paciaroni M. Italian guidelines on thrombolysis indications in ischemic stroke have been revised after the IST-3 trial and Cochrane review. Intern Emerg Med. 2014;9(7):823–4. doi:10.1007/s11739-014-1109-0.CrossRefPubMed

44.

Xu J, Zhang Y, Wei H, Xu Y, Wang M, Cai Z, et al. A comparison of rt-PA thrombolysis guidelines between China and the USA: are changes needed? Neurol Res. 2015;37(1):57–63. doi:10.1179/1743132814Y.0000000415.CrossRefPubMed

45.

Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015. doi:10.1161/STR.0000000000000074.

46.

Jauch EC, Saver JL, Adams Jr HP, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947. doi:10.1161/STR.0b013e318284056a.CrossRefPubMed

47.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7. doi:10.1056/NEJM199512143332401.

48.

Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283(9):1145–50.CrossRefPubMed

49.

Alberts MJ. tPA in acute ischemic stroke: United States experience and issues for the future. Neurology. 1998;51(3 Suppl 3):S53–5.CrossRefPubMed

50.

Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000;31(8):1812–6.CrossRefPubMed

51.

Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. 2000;31(4):811–6.CrossRefPubMed

52.

Grotta JC, Alexandrov AV. tPA-associated reperfusion after acute stroke demonstrated by SPECT. Stroke. 1998;29(2):429–32.CrossRefPubMed

53.

Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol. 2001;58(12):2009–13.CrossRefPubMed

54.

Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology. 1999;53(7):S3–S14.PubMed

55.

Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017–25.CrossRefPubMed

56.

Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A Model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2012. doi:10.1016/j.annemergmed.2012.04.020.PubMedCentralPubMed

57.

Berkhemer OAFP, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11–20. doi:10.1056/NEJMoa1411587.CrossRefPubMed

58.

DA Goyal M, Menon BK, et al. Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke. N Engl J Med. 2015. doi:10.1056/NEJMoa1414905.

59.

Campbell BC MP, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015. doi:10.1056/NEJMoa1414792.

60.

Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Solitaire™ with the intention for thrombectomy as primary endovascular treatment for acute ischemic stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke. Int J Stroke. 2015;10(3):439–48. doi: 10.1111/ijs.12459.

61.

Kidwell CSJR, Alger JR. Design and rationale of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) Trial. Int J Stroke. 2014;9(1):110–6. doi:10.1111/j.1747-4949.2012.00894.x.CrossRefPubMed

62.

Ciccone AVL, Nichelatti M. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368(10):904–13. doi:10.1056/NEJMoa1213701.PubMedCentralCrossRefPubMed

63.

Broderick JPPY, Demchuk AM. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893–903. doi:10.1056/NEJMoa1214300.PubMedCentralCrossRefPubMed

64.

Hacke W, Schellinger PD, Albers GW, Bornstein NM, Dahlof BL, Fulton R, et al. Transcranial laser therapy in acute stroke treatment: results of neurothera effectiveness and safety trial 3, a phase III clinical end point device trial. Stroke. 2014;45(11):3187–93. doi:10.1161/STROKEAHA.114.005795.CrossRefPubMed

65.

Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372(24):2296–306. doi:10.1056/NEJMoa1503780.CrossRefPubMed

66.

Fransen PS, Beumer D, Berkhemer OA, van den Berg LA, Lingsma H, van der Lugt A, et al. MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial. Trials. 2014;15:343. doi:10.1186/1745-6215-15-343.PubMedCentralCrossRefPubMed

67.

Chen M. Cost-effectiveness of endovascular therapy for acute ischemic stroke. Neurology. 2012;79(13 Suppl 1):S16–21. doi:10.1212/WNL.0b013e31826957df.CrossRefPubMed

68.

Leppert MH, Campbell JD, Simpson JR, Burke JF. Cost-effectiveness of intra-arterial treatment as an adjunct to intravenous tissue-type plasminogen activator for Acute Ischemic Stroke. Stroke. 2015;46(7):1870–6. doi:10.1161/STROKEAHA.115.009779.CrossRefPubMed

69.

Zhang L, Zhang RL, Jiang Q, Ding G, Chopp M, Zhang ZG. Focal embolic cerebral ischemia in the rat. Nat Protoc. 2015;10(4):539–47. doi:10.1038/nprot.2015.036.CrossRefPubMed

70.

Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4(3):279–85. doi:10.1007/s12975-012-0209-2.PubMedCentralCrossRefPubMed

71.

Lapchak PA. Recommendations and practices to optimize stroke therapy: developing effective translational research programs. Stroke. 2013;44(3):841–3. doi:10.1161/STROKEAHA.112.680439.CrossRefPubMed

72.

Lyden P, Lapchak P. Sisyphus and translational stroke research. Sci Transl Med. 2012;4(156):156ps20. doi:10.1126/scitranslmed.3005083.PubMed

73.

Gonzalez-Moreno EI, Camara-Lemarroy CR, Gonzalez-Gonzalez JG, Gongora-Rivera F. Glycemic variability and acute ischemic stroke: the missing link? Transl Stroke Res. 2014;5(6):638–46. doi:10.1007/s12975-014-0365-7.CrossRefPubMed

74.

Hafez S, Coucha M, Bruno A, Fagan SC, Ergul A. Hyperglycemia, acute ischemic stroke, and thrombolytic therapy. Transl Stroke Res. 2014;5(4):442–53. doi:10.1007/s12975-014-0336-z.PubMedCentralCrossRefPubMed

75.

Mandava P, Martini SR, Munoz M, Dalmeida W, Sarma AK, Anderson JA, et al. Hyperglycemia worsens outcome after rt-PA primarily in the large-vessel occlusive stroke subtype. Transl Stroke Res. 2014;5(4):519–25. doi:10.1007/s12975-014-0338-x.CrossRefPubMed

76.

Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752–8.

77.

Hoda MN, Bhatia K, Hafez SS, Johnson MH, Siddiqui S, Ergul A, et al. Remote ischemic perconditioning is effective after embolic stroke in ovariectomized female mice. Transl Stroke Res. 2014;5(4):484–90. doi:10.1007/s12975-013-0318-6.PubMedCentralCrossRefPubMed

Titel: Critical Early Thrombolytic and Endovascular Reperfusion Therapy for Acute Ischemic Stroke Victims: a Call for Adjunct Neuroprotection
verfasst von: Paul A. Lapchak
Publikationsdatum: 01.10.2015
Verlag: Springer US
Erschienen in: Translational Stroke Research / Ausgabe 5/2015
Print ISSN: 1868-4483
Elektronische ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-015-0419-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Effects of Low-Frequency Repetitive Transcranial Magnetic Stimulation Combined with Intensive Speech Therapy on Cerebral Blood Flow in Post-Stroke Aphasia

Translational Intracerebral Hemorrhage: a Need for Transparent Descriptions of Fresh Tissue Sampling and Preclinical Model Quality

Rethinking the Roles of Inflammation in the Intracerebral Hemorrhage

Ischemic Stroke Patients with Active Malignancy or Extracardiac Shunts Are More Likely to Have a Right-to-Left Shunt Found by TCD Than Echocardiogram

The Women Independently Living Alone with a Medical Alert Device (WILMA) trial